Autres langues ULTS ASA

Actions

ULTI

NO0010851603

Marché Fermé - Oslo Bors 16:45:00 12/10/2026			Varia. 5j.	Varia. 1 janv.
19,00 ^NOK	-3,31%		-0,25%	+771,56%

03/03/25	Ultimovacs ASA a changé son symbole boursier de ULTI à ZLNA.	CI
03/03/25	Zelluna Immunotherapy AS a acquis Ultimovacs ASA dans le cadre d'une opération de fusion inversée.	CI

Autres langues

09/09	ULTS : List of Representatives 09.09.2026
17/08	Zelluna ASA: Notice of EGM - experienced international biotech executive proposed for election to the Board and Board member steps down
17/08	Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down
17/08	Zelluna ASA: Notice of EGM - experienced international biotech executive proposed for election to the Board and Board member steps down
19/05	ULTS : Poster presented at ASGCT (19.05.2026)
07/05	ULTS : Q1 2026 report and presentation (Presentation)
07/05	ULTS : Q1 2026 report and presentation (Report)
24/04	Zelluna ASA - Annual General Meeting held on April 23, 2026
16/04	ULTS : Capital Marked Update (14.04.2026)
14/04	ULTS : Capital Marked Update (14 April 2026)
26/03	ULTS : Appendix 3 Remuneration Guidelines 2026
26/03	ULTS : Appendix 4 Remuneration Report 2025
26/03	ULTS : Appendix 5 Recommendations by the Nomination Committee 2025
25/03	ULTS : ESG Report 2025
25/03	ULTS : Annual Report 2025 and European Single Electronic Format (ESEF) zip file (Report)
17/03	ULTS : Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
17/03	ULTS : Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours
17/03	Zelluna ASA: Approval and publication of prospectus
17/03	ULTS : Zelluna promotes Emilie Gauthy to Chief Technology Officer
17/03	ULTS : Zelluna ASA – Grant of Share Options
17/03	ULTS : Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
17/03	Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission
17/03	ULTS : Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial
12/02	ULTS : Q4 2025 report and presentation (Report)
12/02	ULTS : Q4 2025 report and presentation (Presentation)